Edwards Lifesciences Corp Stock Price, News & Analysis

Edwards Lifesciences reported Q4 2020 earnings, with sales at $1.2 billion, a 1% increase. TAVR sales rose 2% to $776 million. Adjusted EPS grew 2% to $0.50, while full-year sales reached $4.4 billion, up 1%. However, U.S. TAVR sales declined mid-single digits due to COVID impacts. The company expects 2021 sales growth of 15-20%, with a long-term TAVR opportunity exceeding $7 billion by 2024. Despite some declines in Surgical Structural Heart and Critical Care segments, R&D expenditures increased, focusing on transcatheter innovations.

Edwards Lifesciences (NYSE: EW) will announce its operating results for Q4 2020, ending December 31, 2020, after market close on January 27, 2021. A conference call will follow at 5:00 p.m. ET to discuss the results. Interested participants can join by dialing (877) 704-2848 or (201) 389-0893. An audio replay will be accessible for 72 hours post-call. Edwards Lifesciences is recognized for innovations in structural heart disease and critical care monitoring, aiming to enhance patient care through collaboration with healthcare professionals.

Edwards Lifesciences (NYSE: EW) has initiated the RESTORE clinical trial with the first patient treated for severe degenerative mitral valve regurgitation using the investigational HARPOON Beating Heart Mitral Valve Repair System. This innovative device employs a less invasive technique compared to traditional open-heart surgery, potentially improving recovery for patients. The trial will enroll up to 360 patients across the U.S. and Canada, aiming to establish the device's safety and effectiveness. Edwards also emphasizes its commitment to advancing patient-focused cardiac solutions.

At its annual investor conference on December 10, 2020, Edwards Lifesciences discussed its long-term growth strategy and provided 2021 financial guidance. The company projects global sales between $4.9 and $5.3 billion, with TAVR sales expected between $3.2 and $3.6 billion, reflecting a 15-20% growth rate. Adjusted earnings per share are projected at $2.00 to $2.20. Despite COVID-19 challenges, Edwards anticipates strong growth in TAVR and new product launches across its structural heart portfolio.

Edwards Lifesciences reported Q3 2020 sales of $1.1 billion, a 4% increase from the previous year, with a strong performance in TAVR, which grew 6% to $745 million. Adjusted EPS rose 9% to $0.51, prompting an increase in full-year EPS guidance to $1.85-$1.95. The company noted significant growth potential in TMTT therapies, with $12 million in sales. Overall gross margin was 75.5%. The fourth quarter outlook suggests similar growth to Q3, and the company anticipates double-digit growth in TAVR sales for 2021.

Edwards Lifesciences is set to announce its operating results for the quarter ending September 30, 2020, after market close on October 21, 2020. A conference call to discuss these results will take place at 5:00 p.m. ET on the same day. Participants can join the call by dialing (877) 704-2848 or (201) 389-0893. An audio replay will be available for 72 hours post-call. Further details can be accessed on the company's Investor Relations website.

Edwards Lifesciences (NYSE: EW) announced FDA approval for the KONECT RESILIA aortic valved conduit, the first ready-to-implant solution for bio-Bentall procedures. This innovative device utilizes RESILIA tissue technology, enhancing valve durability and simplifying surgical procedures. The KONECT device aims to streamline emergency surgeries, as up to 30% of Bentall procedures occur in urgent situations. Edwards continues to lead in patient-focused innovations for structural heart disease and is committed to improving patient outcomes through advanced technologies.

On July 13, 2020, Edwards Lifesciences announced a settlement with Abbott to resolve all patent disputes related to transcatheter mitral and tricuspid repair products. This agreement will lift all injunctions and dismiss pending cases worldwide for ten years, allowing Edwards to focus on patient care without litigation distractions. The company will incur a one-time settlement expense in Q2 2020 and ongoing royalty expenses through May 2024. The details of the settlement are confidential, enhancing Edwards' position in the market.

Edwards Lifesciences Corporation (NYSE: EW) will announce its operating results for Q2 2020 on July 23, 2020, after the market closes. A conference call will follow at 5:00 p.m. ET to discuss these results. Investors can participate by dialing (877) 704-2848 or (201) 389-0893. An audio replay will be available for 72 hours post-call. Edwards is a leader in patient-focused innovations for structural heart disease and critical care monitoring, aiming to enhance patient lives through partnerships with healthcare stakeholders.